Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Fig. 4

Published mean AE-QoL (a) and HAE-QoL (b) scores in different patient cohorts. C1-INH(SC) subcutaneous C1-inhibitor, ext extension, HAE hereditary angioedema, HRQoL health-related quality of life, pdC1-INH(IV) plasma-derived intravenous C1-INH, TXA tranexamic acid. Note Mean scores for individual domains for the AE-QoL and HAE-QoL are presented in Additional file 6 and Additional file 8. SC subcutaneous, C1-INH C1-inhibitor, C1-INH(IV) intravenous C1-INH, RhUPH20 recombinant human hyaluronidase, AE-QoL Angioedema Quality of Life Questionnaire, HAE-QoL hereditary Angioedema Quality of Life Questionnaire

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172